Olezarsen Sodium

CHEMBL4650263 Phase 4 Onaylandı Oligonucleotide
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A sodium salt form of olezarsen, an antisense oligonucleotide that reduces liver production of apolipoprotein C-III, thereby lowering triglyceride levels in patients with severe hypertriglyceridemia or familial chylomicronemia syndrome. It helps prevent pancreatitis related to extremely high triglyceride levels.

Etki Mekanizması

Binds to complementary mRNA sequences through Watson-Crick base pairing, modulating gene expression by promoting mRNA degradation via RNase H or altering pre-mRNA splicing.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Binds to complementary mRNA sequences through Watson-Crick base pairing, modulating gene expression by promoting mRNA degradation via RNase H or altering pre-mRNA splicing.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A sodium salt form of olezarsen, an antisense oligonucleotide that reduces liver production of apolipoprotein C-III, thereby lowering triglyceride levels in patients with severe hypertriglyceridemia or familial chylomicronemia syndrome. It helps prevent pancreatitis related to extremely high triglyceride levels.

Binds to complementary mRNA sequences through Watson-Crick base pairing, modulating gene expression by promoting mRNA degradation via RNase H or altering pre-mRNA splicing.

Yes, Olezarsen Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Oligonucleotide.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4650263. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.